Message from Adam Collingwood
Vice President - Marketing, Strategy & Business Development
Joint Replacement
Having just returned from this year's Academy meeting, it was a great pleasure to see many of the subscribers of this newsletter at our booth, evening educational event, and symposium. This was such an exciting time for us from a clinical perspective, with a record number of 22 submissions related to our products accepted and presented! Whether you were present at 2018 Academy or weren't able to make it, we thought you might like highlights of the clinical data presented.
Select a category below to read more about our clinical highlights.
This prospective observational study evaluating the initial experience of two surgeons with robotic-arm assisted TKA demonstrated that surgeons overcame the learning period during the first 10-15 cases using robotic-arm assisted TKA, even with limited surgical experience.1
This 139-patient study is the first prospective randomized control trial to have demonstrated functional superiority of robotic-arm assisted UKA in a more active subgroup of patients undergoing surgery for unicompartmental osteoarthritis.2
This prospective multicenter study of 432 knees demonstrated high midterm survivorship (97.0%) of robotic-arm assisted medial UKA with 91% of the patients either very satisfied or satisfied.3
This 122-patient study showed 99.2% survivorship in high-risk RA patients, plus excellent functional outcomes and ROM and no adverse radiographic findings.4
This retrospective matched case-control study of 400 primary TKAs comparing cementless vs cemented TKAs using the same implant design (Stryker Triathlon; Stryker Inc, Mahwah, NJ), concluded that as the demographics of patients undergoing TKA change to include younger, obese, and more active patients, along with increased life expectancy, the use of a highly porous cementless tibial baseplate may be beneficial in providing long-term durable biologic fixation similar to the success of cementless total hip arthroplasty.5
This matched, controlled study comparing two groups of 136 patients reported no dislocations or intraprosthetic dissociations of primary THAs in patients under 55 years of age using DM bearing systems at a mean follow up of 3.3 years.6
This study of 217 hips implanted with the modular dual mobility (MDM) system examined clinical outcomes after 2 years of implantation and reported that patients appear to have excellent clinical and radiographic outcomes at two-year follow‐up with this implant with no dislocations or ALTR.7
Click here to visit the Academy website to see all submissions which were presented at the meeting this year.
I look forward to continuing to share new clinical data about our products with you as we create the future together!
Sincerely,
Adam Collingwood
A surgeon must always rely on his or her own professional clinical judgment when deciding whether to use a particular product when treating a particular patient. Stryker does not dispense medical advice and recommends that surgeons be trained in the use of any particular product before using it in surgery.
The information presented is intended to demonstrate the breadth of Stryker’s product offerings. A surgeon must always refer to the package insert, product label and/or instructions for use before using any of Stryker’s products. Products may not be available in all markets because product availability is subject to the regulatory and/or medical practices in individual markets. Please contact your sales representative if you have questions about the availability of products in your area. Stryker Corporation or its divisions or other corporate affiliated entities own, use or have applied for the following trademarks or service marks: Mako, Stryker. All other trademarks are trademarks of their respective owners or holders.
GSNPS-COM-131_17104